Ablynx NV - Product Pipeline Review

Global Markets Direct’s, ‘Ablynx NV - Product Pipeline Review - 2016’, provides an overview of the Ablynx NV’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Ablynx NV, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Ablynx NV

The report provides overview of Ablynx NV including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Ablynx NV’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Ablynx NV’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Ablynx NV’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Ablynx NV

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Ablynx NV’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Ablynx NV Snapshot 6

Ablynx NV Overview 6

Key Information ...

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Ablynx NV Snapshot 6

Ablynx NV Overview 6

Key Information 6

Key Facts 6

Ablynx NV - Research and Development Overview 7

Key Therapeutic Areas 7

Ablynx NV - Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products - Monotherapy 11

Pipeline Products - Partnered Products 12

Partnered Products/Combination Treatment Modalities 13

Pipeline Products - Out-Licensed Products 14

Out-Licensed Products/Combination Treatment Modalities 15

Ablynx NV - Pipeline Products Glance 16

Ablynx NV - Late Stage Pipeline Products 16

Phase III Products/Combination Treatment Modalities 16

Ablynx NV - Clinical Stage Pipeline Products 17

Phase II Products/Combination Treatment Modalities 17

Phase I Products/Combination Treatment Modalities 18

Ablynx NV - Early Stage Pipeline Products 19

Preclinical Products/Combination Treatment Modalities 19

Discovery Products/Combination Treatment Modalities 20

Ablynx NV - Drug Profiles 21

caplacizumab 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

ALX-0061 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

ozoralizumab 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

ALX-0171 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

ALX-0141 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

Monoclonal Antibodies for Immunology and Oncology 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

Monoclonal Antibodies for Inflammation and Osteoarthritis 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

Monoclonal Antibodies for Multiple Sclerosis 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Monoclonal Antibody for Undisclosed Indication 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

Monoclonal Antibody to Target c-Met for Multiple Myeloma 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

TLC-520 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

Monoclonal Antibodies to Agonize GITR for Immunology and Oncology 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Monoclonal Antibody 1 for Oncology 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

Monoclonal Antibody 2 for Oncology 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

Ablynx NV - Pipeline Analysis 39

Ablynx NV - Pipeline Products by Target 39

Ablynx NV - Pipeline Products by Route of Administration 40

Ablynx NV - Pipeline Products by Molecule Type 41

Ablynx NV - Pipeline Products by Mechanism of Action 42

Ablynx NV - Recent Pipeline Updates 43

Ablynx NV - Dormant Projects 51

Ablynx NV - Discontinued Pipeline Products 52

Discontinued Pipeline Product Profiles 52

BI-1034020 52

Ablynx NV - Company Statement 53

Ablynx NV - Locations And Subsidiaries 55

Head Office 55

Other Locations & Subsidiaries 55

Appendix 56

Methodology 56

Coverage 56

Secondary Research 56

Primary Research 56

Expert Panel Validation 56

Contact Us 56

Disclaimer 57

List of Tables

List of Tables

Ablynx NV, Key Information 6

Ablynx NV, Key Facts 6

Ablynx NV - Pipeline by Indication, 2016 8

Ablynx NV - Pipeline ...

List of Tables

Ablynx NV, Key Information 6

Ablynx NV, Key Facts 6

Ablynx NV - Pipeline by Indication, 2016 8

Ablynx NV - Pipeline by Stage of Development, 2016 10

Ablynx NV - Monotherapy Products in Pipeline, 2016 11

Ablynx NV - Partnered Products in Pipeline, 2016 12

Ablynx NV - Partnered Products/ Combination Treatment Modalities, 2016 13

Ablynx NV - Out-Licensed Products in Pipeline, 2016 14

Ablynx NV - Out-Licensed Products/ Combination Treatment Modalities, 2016 15

Ablynx NV - Phase III, 2016 16

Ablynx NV - Phase II, 2016 17

Ablynx NV - Phase I, 2016 18

Ablynx NV - Preclinical, 2016 19

Ablynx NV - Discovery, 2016 20

Ablynx NV - Pipeline by Target, 2016 39

Ablynx NV - Pipeline by Route of Administration, 2016 40

Ablynx NV - Pipeline by Molecule Type, 2016 41

Ablynx NV - Pipeline Products by Mechanism of Action, 2016 42

Ablynx NV - Recent Pipeline Updates, 2016 43

Ablynx NV - Dormant Developmental Projects,2016 51

Ablynx NV - Discontinued Pipeline Products, 2016 52

Ablynx NV, Subsidiaries 55

List of Figures

List of Figures

Ablynx NV - Pipeline by Top 10 Indication, 2016 8

Ablynx NV - Pipeline by Stage of Development, 2016 10

Ablynx NV ...

List of Figures

Ablynx NV - Pipeline by Top 10 Indication, 2016 8

Ablynx NV - Pipeline by Stage of Development, 2016 10

Ablynx NV - Monotherapy Products in Pipeline, 2016 11

Ablynx NV - Partnered Products in Pipeline, 2016 12

Ablynx NV - Out-Licensed Products in Pipeline, 2016 14

Ablynx NV - Pipeline by Target, 2016 39

Ablynx NV - Pipeline by Route of Administration, 2016 40

Ablynx NV - Pipeline by Molecule Type, 2016 41

Ablynx NV - Pipeline Products by Mechanism of Action, 2016 42

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports